Authors	Dose/Trial Drug	Risk	Indication
bid = twice a day; CI = confidence interval; HR = hazard ratio; OR = odds ratio; RR = relative risk.
[3]	Rofecoxib <25 mg/qd; rofecoxib >25 mg/qd	OR = 1.47 (0.99–2.17) 3 vs. 58 (1.27–10.17)	Nested case-control study all users
[5]	Celecoxib 200 mg/qd vs. 400 mg bid	3.4%; HR = 3.4 (95% CI, 1.4–7.8)	Sporadic adenoma prevention trial (N = 2,035)
[4]	Rofecoxib 25 mg/qd	RR = 1.92 (95% CI, 1.19–3.11; P = .008)	Chemoprevention sporadic adenoma
[2]	Rofecoxib 25 mg/qd	RR (estimated) = 2.66 (95% CI, 1.03–6.86; P = .04)	Chemoprevention sporadic adenoma median study Rx 7.4 months

References

2. Kerr DJ, Dunn JA, Langman MJ, et al.: Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 357 (4): 360-9, 2007.  [PUBMED Abstract]
   
   
3. Graham DJ, Campen D, Hui R, et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (9458): 475-81, 2005.  [PUBMED Abstract]
   
   
4. Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (11): 1092-102, 2005.  [PUBMED Abstract]
   
   
5. Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (11): 1071-80, 2005.  [PUBMED Abstract]